NASDAQ · CCEL
Healthcare · Medical - Care Facilities
$5.07
Up+$0.02 (+0.40%)
Updated Nov 5, 2026, 4:08 AM
SID Score
5.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CCEL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
CCEL closed at $5.07 after 21 trading sessions, up 29.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $5.1599 | $5.16 | $5.05 | $5.07 | 4.39K |
| Nov 3, 2026 | $5.00 | $5.35 | $5.00 | $5.05 | 6.52K |
| Nov 2, 2026 | $5.30 | $5.35 | $4.95 | $5.35 | 12.53K |
| Oct 30, 2026 | $5.10 | $5.21 | $5.00 | $5.21 | 12.04K |
| Oct 29, 2026 | $5.075 | $5.445 | $5.04 | $5.185 | 8.06K |
| Oct 28, 2026 | $5.15 | $5.35 | $5.125 | $5.125 | 5.31K |
| Oct 27, 2026 | $4.9685 | $5.00 | $4.8338 | $4.96 | 3.27K |
| Oct 26, 2026 | $4.70 | $5.20 | $4.45 | $5.01 | 20.88K |
| Oct 23, 2026 | $4.29 | $4.694 | $4.29 | $4.455 | 1.44K |
| Oct 22, 2026 | $4.57 | $4.57 | $4.2785 | $4.49 | 6.53K |
| Oct 21, 2026 | $4.70 | $4.70 | $4.3288 | $4.6798 | 12.15K |
| Oct 20, 2026 | $4.50 | $4.85 | $4.50 | $4.75 | 6.88K |
| Oct 19, 2026 | $4.35 | $4.80 | $4.345 | $4.65 | 7.9K |
| Oct 16, 2026 | $4.06 | $4.46 | $3.76 | $4.42 | 10.74K |
| Oct 15, 2026 | $4.05 | $4.46 | $3.65 | $3.65 | 16.73K |
| Oct 14, 2026 | $4.375 | $4.375 | $4.14 | $4.15 | 9.6K |
| Oct 13, 2026 | $4.15 | $4.52 | $4.15 | $4.30 | 15.24K |
| Oct 12, 2026 | $4.75 | $4.89 | $4.475 | $4.50 | 43.77K |
| Oct 9, 2026 | $4.00 | $4.47 | $4.00 | $4.36 | 5.47K |
| Oct 8, 2026 | $4.04 | $4.72 | $3.70 | $4.17 | 50.42K |
| Oct 7, 2026 | $3.90 | $3.9327 | $3.90 | $3.91 | 4K |
The latest Smart Investors Daily articles mentioning CCEL.
Company
Market Activity
Research & News
CCEL research
Company profile and research snapshot.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2025 | Maxim Group | Hold | — |
| Mar 4, 2025 | Maxim Group | Buy | — |
| Aug 29, 2022 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 16, 2026
Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics (NASDAQ:TCRT)
Benzinga · Oct 12, 2026
Goodyear names Joe Hinrichs chair, Pomdoctor faces Nasdaq delisting; Cryo-Cell earnings rise; SMP and Quantum announce CFO changes.
ChartMill · Oct 9, 2026
Cryo-Cell (CCEL) Q3 EPS crushed estimates at $0.16, but revenue stayed flat at $7.82M. See the profit surprise, market reaction, and key risks.
Yahoo · Oct 9, 2026
OLDSMAR, Fla., October 09, 2026--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the "Company", "Cryo-Cell"), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CCEL.
